Hua Medicine Announces 2024 Annual Results - HuaTangNing completed its first full year for reimbursement under the National Reimbursement D ...

Ultimately, Chimerix’s board went with Jazz’s offer due to its cash payable nature and the recent downward trend in biopharma ...

In its fourth quarter 2024 investor letter, RiverPark Large Growth Fund emphasized stocks such as Eli Lilly and Company (NYSE:LLY). Eli Lilly and Company (NYSE:LLY) is a pharmaceutical company ...

Hims & Hers has risen since November 2024, outperforming the S&P 500. Click here to see why HIMS stock is a Buy.

Nonetheless, there have been effects on businesses that specifically support the pharmaceutical ... Head of Americas Equities Sales Trading at Goldman, wrote in a letter to clients that biotech ...

Gold price has rallie over 1.00% at one point on Thursday after fresh tariff comments.

The EUR/USD pair rebounds from over a three-week low, around the 1.0735-1.0730 area touched during the Asian session on ...

Indian pharmaceutical ... sales, profit margins may shrink due to intense competition in the US generics market. Additionally, regulatory risks persist, with compliance issues, warning letters ...

“Three of our portfolio products with blockbuster sales potential ... received a termination letter from Acrotech, which holds exclusive worldwide rights to Evomela. The letter alleges that ...

Fintel reports that on March 18, 2025, Evercore ISI Group initiated coverage of West Pharmaceutical Services (NYSE:WST) with a Outperform recommendation. As of March 3, 2025, the average one-year ...